ImmunityBio (IBRX) Q3 2026 earnings review
ImmunityBio wins wider bladder cancer approval, but quarterly sales dip
ImmunityBio, the maker of the Anktiva bladder cancer immunotherapy, won major clinical and regulatory victories even as its quarterly drug sales unexpectedly slipped. Third-quarter net product revenue rose 53% from a year ago to $49 million, but by our math fell 4% from the second quarter. Chief executive Richard Adcock pointed to growing doctor interest as the company won expanded US approval for papillary bladder tumors in October and met its main goal in a trial for untreated patients.
| Net product revenue | $48.7M +53% from a year ago, -4% from last quarter |
|---|---|
| Net loss, excluding one-offs | $97.9M +35% from a year ago |
| Cash and marketable securities | $334.3M $357.4M last quarter |
| Untreated bladder cancer FDA filing | Unchanged planned for Q4 2026 after trial win |
⚖️ Verdict: 🟢 Bullish
The story got better because the early FDA approval for papillary tumors and the positive first-line trial expand Anktiva's addressable patient population. Those October and November milestones arrived right after the original US bladder cancer indication showed signs of plateauing in the third quarter. One caution: operating losses excluding one-offs widened to $98 million as trial and commercial spending jumped, keeping quarterly cash burn high at $75 million.
The question now is whether the third-quarter sales dip was a temporary pause before the label expansion or a sign of deeper pricing and demand friction. Either the new papillary approval and European rollout restart sequential revenue growth immediately, or rising commercial costs continue to outpace revenue and force more dilutive financing. Fourth-quarter product revenue and unit volumes will tell.
🐂 Bull Case
FDA Approval Opens Larger Bladder Cancer Market
"The recent label expansion represents an important opportunity to broaden access to ANKTIVA for a significantly larger patient population," chief executive Richard Adcock said. Anktiva is ImmunityBio's flagship immunotherapy drug for non-muscle invasive bladder cancer (NMIBC), a disease where tumors grow in the inner lining of the bladder.
On October 14, the US Food and Drug Administration approved Anktiva alongside Bacillus Calmette-Guérin (BCG), a standard bladder treatment, for patients with "high-grade papillary-only tumors". Regulators acted nearly three months ahead of their January 2027 deadline. Previously, doctors could only prescribe the drug on-label if a patient also had carcinoma in situ, a flat and aggressive bladder lesion.
This approval matters because papillary-only patients represent a broader group of bladder cancer cases, and national treatment guidelines already recommended Anktiva for them earlier this year. In addition, a study in The Journal of Urology showed 84% of responding patients avoided bladder removal at three years, giving urologists long-term evidence to prescribe the therapy.
What to watch: fourth-quarter net product revenue, which will cover the first ten weeks of commercial sales under the expanded US label. A return to quarter-on-quarter revenue growth would show that doctors quickly acted on the wider approval.
Trial Win Sets Up First-Line Bladder Filing
ImmunityBio wants to move Anktiva into earlier stages of bladder cancer treatment. Today, patients only receive the drug after standard BCG therapy stops working. The biotech group runs a randomized study called QUILT-2.005 that tests Anktiva plus BCG against BCG alone in BCG-naïve patients, who have never received standard therapy.
In November, the developer announced that Cohort A of this trial met its primary goal, showing a benefit for patients taking the combination. That result keeps the company on schedule to file a supplemental application with US regulators during the fourth quarter of 2026. Winning approval in untreated patients would multiply the eligible patient pool beyond salvage therapy.
What to watch: the exact clinical data from Cohort A and confirmation that the FDA accepts the fourth-quarter application for review. Clear efficacy margins over BCG alone would strengthen the case for first-line adoption.
European Launch Begins as Approvals Reach 35
Until now, US urologists generated nearly all of Anktiva's revenue. ImmunityBio has spent the past year building an international network, partnering with Accord Healthcare in Europe and Rafa Laboratories in Israel to sell the bladder cancer treatment abroad.
In early Q4, doctors treated the first commercial patients in Europe, and Israel approved the therapy in November. Anktiva now holds approvals across 35 countries in six regulatory jurisdictions, including the United Arab Emirates. Opening European clinics gives the group a second commercial region just as US quarterly sales growth paused.
What to watch: whether management breaks out international revenue or European patient volumes in the full-year report. Early reorders from European hospitals would prove that overseas approvals are turning into collected sales.
🐻 Bear Case
Drug Sales Shrank From Last Quarter
"We continue to see more physicians prescribing ANKTIVA to multiple patients and growing physician interest in our chemotherapy-free approach in the U.S. and Europe," Adcock said. Management highlighted that third-quarter net product revenue rose 53% from a year ago to $48.7 million, and nine-month sales climbed 92% to $143.6 million.
However, comparing sales with last year hides a stall during the quarter. By our math, net product revenue fell 3.8% from the $50.7 million recorded in the second quarter. That drop broke a streak of double-digit sequential increases since launch, and the company did not report unit volume growth this quarter after highlighting a 168% volume jump in the first quarter.
- Q1 2026 net product revenue: $44.2 million, up 15.3% from Q4 2025
- Q2 2026 net product revenue: $50.7 million, up 14.7% from Q1 2026
- Q3 2026 net product revenue: $48.7 million, down 3.8% from Q2 2026
The sequential dip matters because it shows that the initial carcinoma in situ indication may be saturating its easiest-to-reach US clinics, or that higher gross-to-net discounts are weighing on revenue per dose. Without the October label expansion, the core US launch was losing momentum.
What to watch: whether the upcoming quarterly filing reveals unit volume trends or higher commercial rebates for the third quarter. A drop in shipped units would indicate slowing clinical demand prior to the papillary label expansion.
Trial and Launch Costs Widened Operating Losses
Higher revenue did not move ImmunityBio closer to breaking even in the third quarter. Its operating loss widened to $78.0 million, compared with $55.6 million a year ago and $61.7 million in the second quarter, because clinical and commercial spending outpaced sales.
Research and development costs — the money spent running trials and producing drug supply — jumped 39.6% from a year ago to $71.5 million, though they fell 13.3 percentage points as a share of revenue to 146.5%. Selling, general and administrative expenses — sales force pay, marketing and legal overhead — rose 48.8% to $54.0 million, or 110.6% of revenue, down 2.6 percentage points from a year ago.
What to watch: total operating expenses in the fourth quarter as the European rollout and papillary marketing campaign ramp up. If overhead keeps growing by $10 million or more a quarter, new bladder cancer sales will not reduce the operating deficit.
Cash Burn Rose and Financing Obligations Swelled
ImmunityBio ended September with $334.3 million in cash and marketable securities, down 6.5% from $357.4 million in June by our math. Operations burned $75.3 million in cash during the quarter, up 13.3% from $66.5 million in the second quarter, while financing activities brought in $53.0 million.
Meanwhile, its revenue interest liability — a financing arrangement that pays backers a share of future sales — rose 31.3% over the first nine months to $426.3 million. That liability generated $17.4 million in quarterly interest expense, up from $12.3 million a year ago. At the current burn rate, existing liquidity covers roughly four to five quarters of operations.
What to watch: cash raised from financing activities and the revenue interest liability balance at year-end. Continued reliance on royalty-backed debt or equity sales each quarter reduces the return left for common shareholders.
👓 Other Themes
US Drug Pricing Policy Added to Risk Warnings
In its forward-looking disclosures, ImmunityBio highlighted risks around evolving most-favored-nation drug pricing rules in the United States. The company warned that linking US reimbursement to international prices could affect product launch timing, market access and future revenues both domestically and abroad just as it begins commercial sales across Europe.
💲 Other KPIs
The net loss excluding one-offs — which strips out $77.9 million of non-cash accounting charges on debt and warrants and $8.7 million of stock compensation — widened by 35.2% from a year ago and 20.9% from last quarter. Higher clinical trial spending and commercial expansion drove the larger deficit.
The weighted-average diluted share count rose 12.1% from 946.6 million a year ago, and increased from 1,050.1 million in the second quarter. Ongoing equity financings and partial loan conversions in early 2026 expanded the share base to fund clinical and commercial operations.
The fair value of the related-party convertible note climbed 75.0% from $477.1 million at the end of 2025, and rose from $774.4 million in the second quarter. Related-party interest expense on this debt totaled $14.6 million in the third quarter, down slightly from $15.3 million a year ago.
🔮 Guidance
Unchanged. The biotechnology group remains on schedule to submit its supplemental application to the FDA in the fourth quarter of 2026 for Anktiva plus BCG in untreated bladder cancer patients, after Cohort A of the QUILT-2.005 trial met its primary endpoint in November.
❓ Key Questions
Why did Anktiva revenue fall from the second quarter?
Net product revenue dropped 3.8% from the prior quarter to $48.7 million, and the release omitted unit volume figures. Investors need to know if shipped vials declined or if higher rebates reduced the net price per dose.
When will management provide a revenue outlook?
Anktiva has been on the US market for ten quarters and just won its papillary-only label expansion, yet the company still provides no quarterly or annual sales forecast.
What were the exact response rates in QUILT-2.005 Cohort A?
ImmunityBio announced that Cohort A met its primary endpoint in untreated bladder cancer patients, but did not publish the complete response rate or duration gap versus BCG alone ahead of the FDA filing.
Where do FDA discussions stand for lung cancer?
Earlier in 2026, management planned to discuss an accelerated approval pathway for metastatic non-small cell lung cancer with the FDA, and the current release gave no timeline for that regulatory meeting.